<ul data-eligibleForWebStory="false"><li>Swiss BioTech platform NUCLIDIUM, based in Basel, raised €84 million in a Series B financing round led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR.</li><li>NUCLIDIUM is developing a proprietary copper-based theranostic platform for diagnosing and treating metastatic prostate, neuroendocrine tumors, and breast cancer, with a focus on women's health.</li><li>The company's copper isotopes (Copper-61 for diagnostics and Copper-67 for therapeutics) aim to overcome limitations in radiotheranostics and improve clinical efficacy in cancer treatment.</li><li>The funding will support NUCLIDIUM's clinical development, expand its production and manufacturing network, and advance its Copper-61/Copper-67 theranostic pipeline across multiple oncology indications.</li></ul>

Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer

Discover more